This article is from:Interface NewsOriginal Title: "National Healthcare Security Administration: Azvudine Tablets and Qingfei Paidu Granules Successfully Negotiated, Paxlovid Failed to Enter the Medical Insurance Drug List Due to High Quotation", Header Image Source: Visual China
National Healthcare Security Administration website, January 8th message: The 2022 National Medical Insurance Drug Catalog negotiation work officially ended on January 8, 2023. The person in charge of the Medical Management Department of the National Healthcare Security Administration introduced the situation regarding COVID-19 treatment drugs participating in the medical insurance drug catalog negotiation.
This year, there are Azvudine Tablets, and the combination package of Nirmatrelvir Tablets/Ritonavir Tablets.(hereinafter referred to as "Paxlovid")Three COVID-19 treatment drugs, including Qingfei Paidu Granules, participated in the negotiation through procedures such as independent application by enterprises, formal review, and expert evaluation.Azvudine Tablets and Qingfei Paidu Granules successfully negotiated, Paxlovid failed due to high bid by its manufacturer, Pfizer, Inc.
The official indicated that although Paxlovid failed to be included in the medical insurance catalog through negotiation, according to the recent "Notice on Optimizing the Medical Insurance Policies for Treatment Expenses of Patients Infected with COVID-19 after Implementing 'Category B Management'" jointly issued by the National Healthcare Security Administration and other relevant departments,(hereinafter referred to as the "Notice")Request, "Diagnosis and Treatment Protocol for Novel Coronavirus Infection(Trial Tenth Edition)》All therapeutic drugs inIncluding Paxlovid, Azvudine Tablets, Molnupiravir Capsules, and Sanhan Huashi Granules, all will be temporarily covered by medical insurance until March 31, 2023. During this period, insured patients infected with the coronavirus can enjoy medical insurance reimbursement policies when using these drugs.
In addition, after Azvudine Tablets and Qingfei Paidu Granules were included in the national medical insurance drug list through this negotiation, there are already more than 600 drugs in the national medical insurance drug list for treating COVID-19 symptoms such as fever and cough. At the same time, to meet the needs of treating coronavirus-infected patients across regions, local medical insurance departments, in combination with the operational status of local medical insurance funds, have temporarily incorporated a group of drugs for symptomatic COVID-19 treatment into the medical insurance payment scope of their respective regions. Overall, the variety of medical insurance-reimbursable drugs for treating coronavirus infections is extensive.
This person in charge also stated that the National Healthcare Security Administration recently issued the "Guidance on the Formation of Prices for COVID-19 Treatment Drugs (Trial)," which adopts full-cycle, multi-level measures to guide companies to set open, transparent, and reasonable prices for newly launched antiviral treatment drugs needed to prevent and treat Coronavirus infection.
Next, the National Healthcare Security Administration will continue to adhere to a people-centered approach, implement the decisions and arrangements of the CPC Central Committee and the State Council, fully carry out the adjustment work of the medical insurance drug list, include more new and effective drugs in the medical insurance drug list, effectively reduce the burden of medical expenses for the public, and help resolve the concerns of the people regarding medical treatment.
This article is from:Interface News